Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This educational activity is supported by educational grants from Agios Pharmaceuticals, Inc; AstraZeneca; Genomic Health Inc; Merck & Co, Inc; and Taiho Pharmaceutical Co.

Virtual Tumor Board®: Integrating Emerging Testing Methodologies Into Optimal Treatment Planning in GI Cancers

Release Date: April 30, 2021
Expiration Date: April 30, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in gastrointestinal malignancies considering case studies and applying recent clinical trial data to real-world scenarios. This activity will serve as an update on the emerging trends in molecular testing for patients with gastrointestinal cancers.

This educational activity is an archive of the live virtual symposium held on April 15, 2021.

Acknowledgement of Commercial Support

This educational activity is supported by educational grants from Agios Pharmaceuticals, Inc; AstraZeneca; Genomic Health Inc; Merck & Co, Inc; and Taiho Pharmaceutical Co.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward pathologists, medical oncologists, and other health care professionals interested in the treatment of GI cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Outline key biomarkers and molecular testing that guide treatment decision-making in GI cancer management
  • Assess emerging liquid biopsy approaches in GI cancer settings that allow for screening, treatment monitoring, and prediction of relapse
  • Evaluate safety and efficacy data for emerging biomarker and molecular testing–guided treatment options in GI cancer settings
  • Integrate testing strategies that match patients to particular treatment strategies in GI cancer case management scenarios

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Faculty

Tanios Bekaii-Saab, MD, FACP
Tanios Bekaii-Saab, MD, FACP
Professor, Mayo Clinic College of Medicine and Science
Leader, Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Chair, ACCRU Research Consortium
Phoenix, AZ

Disclosures: Research Funding (to institution): AbGenomics Holdings, Amgen, Array BioPharma, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis Oncology, Eli Lilly, Genentech, Incyte, Ipsen Biopharmaceuticals, Merck, Seagen; Consulting (to institution): Array BioPharma, Bayer, Genentech, Incyte, Ipsen Biopharmaceuticals, Merck, Seagen; Consulting (to self): Boehringer Ingelheim, Daiichi Sankyo, Eisai, Janssen Pharmaceuticals, Natera, Sobi, Treos Bio; IDMC/DSMB (to self): AstraZeneca, Exelixis, Eli Lilly, PanCAN, 1Globe Health Institute; Scientific Advisory Board: Imugene, Immuneering Corporation, Sun BioPharma; Other: Inventions/Patents: WO/2018/183488 and WO/2019/055687.

Johanna Bendell, MD
Johanna Bendell, MD
Chief Development Officer
Director, GI Cancer Research Program
Director, Drug Development Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

Disclosures: Grant/Research Support (all paid to institution): AbbVie, Acerta Pharma, ADC Therapeutics, Agios, Amgen, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma, AstraZeneca, AtlasMedx, Bayer, BeiGene, Bellicum, Boehringer Ingelheim, Bicycle Therapeutics, Blueprint Medicines, Bristol Myers Squibb, Boston Biomedical, CALGB, Calithera, Celgene, Celldex Therapeutics, Cyteir Therapeutics, CytomX Therapeutics, Daiichi Sankyo, eFFECTOR Therapeutics, Eisai, Eli Lilly and Company, EMD Serono, Evelo, Five Prime, Forma Therapeutics, Forty Seven, Foundation Medicine, Genentech/Roche, Gilead, Gossamer Bio, GlaxoSmithKline, Harpoon Therapeutics, Hutchison MediPharma, IGM Biosciences, ImClone Systems, Incyte, Innate Pharma, Ipsen, Jacobio, Kolltan Pharmaceuticals, Leap Therapeutics, MabSpace Biosciences, MacroGenics, Marshall Edwards, MedImmune, Merck, Merrimack Pharmaceuticals, Mersana Therapeutics, Merus, Millennium Pharmaceuticals, Morphotex, Nektar, NeoImmuneTech, NGM Biopharmaceuticals, Novartis, NovoCare, Numab, OncoGenex Pharmaceuticals, OncoMed, Ongologie, Onyx Pharmaceuticals, Pfizer, Pieris Pharmaceuticals, Prelude Therapeutics, PureTech Health, Regeneron, Relay Therapeutics, Repare Therapeutics, Revolution Medicines, Rgenix, Sanofi, Scholar Rock, Seagen, Shattuck Labs, Sierra, Stemcentrx, SynDevRex, Synthorx, Taiho, Takeda, Tarveda Therapeutics, Tempest Therapeutics, TG Therapeutics, TRACON Pharmaceuticals, Treadwell Therapeutics, Tyrogenex, Unum Therapeutics, Vyriad, Zymeworks; Consultant (all paid to institution): Agios, Amgen, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bicycle Therapeutics, Bristol Myers Squibb, Celgene, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Evelo, Five Prime, Forma Therapeutics, Fusion Pharmaceuticals, Genentech/Roche, Gilead, GlaxoSmithKline, Incyte, Innate Pharma, Ipsen, Janssen, Leap Therapeutics, MacroGenics, MedImmune, Merck, Merrimack Pharmaceuticals, Moderna Therapeutics, Molecular Partners, Novartis, OncoGenex, OncoMed, Pfizer, PhoenixBio, Piper Biotech, Prelude Therapeutics, Relay Therapeutics, Samsung Bioepis, Sanofi, Seagen, Taiho, Tanabe Research Laboratories, TD2 (Translational Drug Development), TG Therapeutics, Tizona Therapeutics, Tolero Pharmaceuticals, Torque; Other Support (all paid to institution): ARMO BioSciences, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Forma Therapeutics, Genentech/Roche, Gilead, Ipsen, MedImmune, Merck, Novartis, OncoGenex, OncoMed, Taiho.

Rondell P. Graham, MBBS
Rondell P. Graham, MBBS
Associate Professor, Gastrointestinal/Liver Pathology
Molecular Pathology, Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN

Disclosures: No relevant financial relationships with ineligible companies.

Yelena Y. Janjigian, MD
Yelena Y. Janjigian, MD
Associate Professor
Chief, Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Bayer Healthcare, Bristol Myers Squibb, Cycle for Survival, Department of Defense, Eli Lilly and Company, Fred’s Team, Genentech/Roche, Merck, National Cancer Institute, Rgenix; Consultant: AstraZeneca, Basilea Pharmaceutica, Bayer Healthcare, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Imugene, Merck, Merck Serono, Pfizer, Rgenix, Seagen, Zymeworks; Stock/Shareholder: Rgenix.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By